These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37661067)

  • 1. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
    Huttner A; Agnandji ST; Engler O; Hooper JW; Kwilas S; Ricks K; Clements TL; Jonsdottir HR; Nakka SS; Rothenberger S; Kremsner P; Züst R; Medaglini D; Ottenhoff T; Harandi AM; Siegrist CA; ; ;
    Clin Microbiol Infect; 2023 Dec; 29(12):1587-1594. PubMed ID: 37661067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
    Huttner A; Agnandji ST; Combescure C; Fernandes JF; Bache EB; Kabwende L; Ndungu FM; Brosnahan J; Monath TP; Lemaître B; Grillet S; Botto M; Engler O; Portmann J; Siegrist D; Bejon P; Silvera P; Kremsner P; Siegrist CA; ; ;
    Lancet Infect Dis; 2018 Jul; 18(7):738-748. PubMed ID: 29627147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
    Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
    Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
    Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
    PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
    Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
    Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
    Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK
    Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.
    Alabi A; Kokou K; Mahmoudou S; Kavishna R; Nakka SS; Rothenberger S; Musangomunei FP; Olubiyi BF; Bie-Ondo JC; Kabwende AL; Velavan TP; ; Medaglini D; Nakaya HI; Engler O; Harandi AM; Siegrist CA; Kremsner PG; Agnandji ST
    J Infect; 2024 Oct; 89(4):106237. PubMed ID: 39121969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.
    Regules JA; Beigel JH; Paolino KM; Voell J; Castellano AR; Hu Z; Muñoz P; Moon JE; Ruck RC; Bennett JW; Twomey PS; Gutiérrez RL; Remich SA; Hack HR; Wisniewski ML; Josleyn MD; Kwilas SA; Van Deusen N; Mbaya OT; Zhou Y; Stanley DA; Jing W; Smith KS; Shi M; Ledgerwood JE; Graham BS; Sullivan NJ; Jagodzinski LL; Peel SA; Alimonti JB; Hooper JW; Silvera PM; Martin BK; Monath TP; Ramsey WJ; Link CJ; Lane HC; Michael NL; Davey RT; Thomas SJ;
    N Engl J Med; 2017 Jan; 376(4):330-341. PubMed ID: 25830322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein.
    Mahon BE; Simon J; Widdowson MA; Samai M; Rogier E; Legardy-Williams J; Liu K; Schiffer J; Lange J; DeByle C; Pinner R; Schuchat A; Slutsker L; Goldstein S
    J Infect Dis; 2021 Dec; 224(11):1907-1915. PubMed ID: 34013349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
    ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
    CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
    Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG;
    Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
    Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
    J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
    Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
    Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
    Huttner A; Siegrist CA
    Expert Rev Vaccines; 2018 Dec; 17(12):1105-1110. PubMed ID: 30422031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
    Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
    Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
    Dahlke C; Kasonta R; Lunemann S; Krähling V; Zinser ME; Biedenkopf N; Fehling SK; Ly ML; Rechtien A; Stubbe HC; Olearo F; Borregaard S; Jambrecina A; Stahl F; Strecker T; Eickmann M; Lütgehetmann M; Spohn M; Schmiedel S; Lohse AW; Becker S; Addo MM;
    EBioMedicine; 2017 May; 19():107-118. PubMed ID: 28434944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.
    Waltenburg MA; Kainulainen MH; Whitesell A; Nyakarahuka L; Baluku J; Kyondo J; Twongyeirwe S; Harmon J; Mulei S; Tumusiime A; Bergeron E; Haberling DL; Klena JD; Spiropoulou C; Montgomery JM; Lutwama JJ; Makumbi I; Driwale A; Muruta A; Balinandi S; Shoemaker T; Cossaboom CM
    Vaccine; 2024 Sep; 42(22):126031. PubMed ID: 38880693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.